Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Lilly's next obesity drug just cut an average of 58 pounds
Fifty-eight pounds. That’s how much weight patients lost on average at the end of 48 weeks when taking Eli Lilly’s next-generation obesity treatment.
Annalee Armstrong
Jun 26, 2023 8:45pm
Aldeyra's dry eye disease drug scores phase 3 conjunctivitis win
Jun 15, 2023 9:30am
Pfizer's phase 3 hemophilia gene therapy beats standard of care
Dec 29, 2022 10:36am
Protalix eyes 2nd try at Fabry med in 2H22
Mar 18, 2022 9:22am
Eiger's COVID-19 drug headed to FDA with 50% hospital reduction
Mar 17, 2022 8:00am
Ascendis scores in phase 3 trial, a boost to endocrine portfolio
Mar 14, 2022 11:15am
